Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 8/20 | 0.65 |
| ▸ | FLT3 | P36888 | 2/20 | 0.56 |
| ▸ | BTK | Q06187 | 2/20 | 0.56 |
| ▸ | BRD4 | O60885 | 8/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1197568 | 0.91 | FLT3 (0.57) | PAK1FLT3BTKBRD4CCNT1 | |
| SCHEMBL1198229 | 0.89 | SYK (0.58) | PAK1FLT3BTKBRD4CCNT1 | |
| SCHEMBL1198366 | 0.86 | PAK1 (0.57) | PAK1FLT3BTKCCNT1CCNE1 | |
| SCHEMBL1198204 | 0.83 | SYK (0.59) | PAK1FLT3BTKBRD4CCNT1 | |
| SCHEMBL1197980 | 0.81 | BCL6 (0.63) | PAK1FLT3BTKBRD4EGFR | |
| SCHEMBL1197860 | 0.80 | SYK (0.59) | PAK1FLT3BTKBRD4CCNT1 | |
| SCHEMBL1196953 | 0.80 | SYK (0.58) | FLT3BTKCCNT1CCNE1CDK2 | |
| SCHEMBL1197639 | 0.80 | CDK2 (0.64) | FLT3BTKBRD4CCNT1CCNE1 | |
| SCHEMBL1197006 | 0.79 | FLT3 (0.51) | PAK1FLT3BTKBRD4CCNT1 | |
| SCHEMBL1196956 | 0.78 | FLT3 (0.63) | PAK1FLT3BTKBRD4CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834024-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | claimed |
| US-20080260754-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | claimed |
| US-8299087-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20110027856-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-7834024-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080260754-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008118823-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080260754-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | PAK1 696/4885FLT3 46/4885BTK 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.